Up to 91% of patients reached EASI-75 and up to 67% reached IGA 0/1 at week 152, with no new safety signals, according to Galderma's EADV 2026 data.
|Articles|June 17, 2008
Medicis expands with purchase of LipoSonix
Scottsdale, Ariz. - Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.
Advertisement
Scottsdale, Ariz.
- Medicis' purchase of LipoSonix, an ultrasound technology used to target fat cells, will launch the company into the international marketplace and the body-contouring business, the East Valley Scottsdale Tribune reports.
The company is set to pay $300 million for LipoSonix, with $150 million to be paid up front to acquire the privately-owned company along with its 40 employees and research facilities. Medicis will pay the other $150 million after the U.S. approval process is complete and the technique reaches certain worldwide goals, according to the Tribune.
Advertisement
Related to this article
Two studies presented at EADV 2026 highlight misinformation and dermatologic complications linked to viral skincare routines on social media.
Phase 2 data presented at EADV 2026 showed daxdilimab significantly reduced disease activity and improved response rates in treatment-refractory DLE.
Presented as a late breaker at EADV 2026, mid-dose zumilokibart achieved EASI-75 in 65.9% of adults with atopic dermatitis vs 23.4% with placebo at week 16.
This review of the latest dermatological studies includes insights on ruxolitinib for lichen planus, early vitiligo treatment, psoriasis response, AD disease control, and PFB management.
EADV 2026 data highlight dupilumab’s effects on growth, quality of life, disease control, and itch across multiple dermatologic diseases.
The FDA approved therapies for melanoma, dermatomyositis, superficial basal cell carcinoma, and adolescent alopecia areata, while TYK2 inhibitors and rare disease filings advanced toward 2027 decisions.
Dermatology Times is looking back on the top stories in dermatology from the month of September.
Advertisement
Advertisement
Trending on Dermatology Times
1
Late Breaking: Zumilokibart Meets Primary End Point in Phase 2 Atopic Dermatitis Trial
2
Dupilumab Data at EADV 2026 Highlight Outcomes Across AD, CSU, and Prurigo Nodularis
3
Daxdilimab Improves Disease Activity in Treatment-Refractory Discoid Lupus in Phase 2 Trial
4
Dermatology FDA and Pipeline Review: Q3 2026 Approvals and Readouts
5